View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
June 13, 2018

Advaxis doses first patient in Phase l trial of ADXS-NEO

Advaxis has dosed the first patient in a Phase l trial of ADXS-NEO for the treatment of metastatic non-small cell lung cancer (NSCLC), metastatic microsatellite stable colon cancer and metastatic squamous head and neck cancer.

Advaxis has dosed the first patient in a Phase l trial of ADXS-NEO for the treatment of metastatic non-small cell lung cancer (NSCLC), metastatic microsatellite stable colon cancer and metastatic squamous head and neck cancer.

The first patient dosed with ADXS-NEO is affected by non-small cell lung cancer.

The open-label, dose-escalation, multi-centre clinical trial is currently being conducted in the US.

As part of the trial, Advaxis will conduct a biopsy of the patients and then develop an investigational personalised treatment for each patient based on an analysis of their tumour neoantigen mutations, which will be ready to be dosed within eight weeks of the initial biopsy.

Around 48 subjects are expected to be enrolled in the trial, which is expected to be completed by September 2020.

“This programme brings our clinically validated Lm Technology to the cutting-edge area of neoantigen immuno-oncology.”

Advaxis president and CEO Kenneth Berlin said: “This programme brings our clinically validated Lm Technology to the cutting-edge area of neoantigen immuno-oncology.

“We are committed to realising the potential of ADXS-NEO to mobilise patients’ immune systems against mutations that accumulate within and contribute to the development of their cancer, and to bring the potential benefits of our technology to more patients and their families.”

ADXS-NEO is currently being investigated as a personalised Listeria monocytogenes (Lm)-based immunotherapy designed to produce an immune response against mutation-derived tumour-specific neoantigens identified through DNA sequencing of a patient’s own tumours.

Advaxis had previously partnered with Amgen in order to develop ADXS-NEO.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena